real peptides FAQ

Freeze the reconstituted peptide in single-use aliquots at −80°C to halt degradation. Do not use a standard −20°C freezer, as the freeze-thaw cycling from auto-defrost mechanisms denatures peptides. Thaw each aliquot at 4°C immediately before use and never refreeze. Peptides subjected to multiple freeze-thaw cycles show 20–40% potency loss due to ice crystal formation disrupting tertiary structure. For studies requiring daily dosing over weeks, lyophilize peptide into single-dose vials rather than reconstituting bulk volumes.

Freeze aliquots at −20°C or −80°C immediately after reconstitution and thaw only once before use. Frozen melatonin retains 85–90% potency for 6–12 months when stored in amber glass vials with minimal headspace and no repeated freeze-thaw cycles. Thaw frozen aliquots passively at 4°C rather than at room temperature or under warm water. Rapid thawing creates localized temperature gradients that destabilize the solution. One freeze-thaw cycle is acceptable; two or more cycles cause cumulative ice crystal damage and oxidative concentration effects that reduce potency by 20–30%. If your experimental timeline requires repeated dosing over months, divide the stock into enough aliquots that each vial is thawed, used, and discarded without refreezing.

Discard it. If the cold pack was melted on arrival or the package felt room temperature, the peptide has likely exceeded 8°C for an unknown duration. SS-31 storage failures during shipping are the supplier's responsibility, not yours. Contact the supplier immediately for replacement. At Real Peptides, we document every shipment's cold chain compliance and replace any vial that arrives outside the 2–8°C range at no cost. Attempting to use a warm-shipped vial introduces two problems: you can't confirm potency without HPLC analysis, and even partial degradation means your experimental results are based on an unknown effective dose. If you're conducting dose-response studies or mechanistic research on mitochondrial function, starting with degraded SS-31 invalidates your data. The cost of replacing one vial is trivial compared to wasted research time on compromised peptide.

Expose yourself to bright light (>2,500 lux) during the biological morning of your destination time zone and take 0.5–3 mg melatonin 2 hours before your desired bedtime at the destination. Light exposure advances or delays the circadian clock depending on timing. Morning light in your destination advances the clock eastward, while evening light delays it westward. Melatonin accelerates this shift by directly phase-advancing the SCN when taken during the early biological night. A controlled trial in jet-lagged travelers found this combination reduced circadian realignment time from 7–9 days to 2–4 days compared to light exposure alone.

Use subcutaneous or intraperitoneal injection and accept that brain exposure will be 5–15% of plasma concentration. The blood-brain barrier restricts peptide passage due to Pe-22-28's hydrophilic residues and molecular weight (approximately 800 Da). Published rodent protocols using systemic delivery compensate by increasing dose. 2–5 mg/kg subcutaneously achieves measurable cognitive effects in Morris water maze and novel object recognition, compared to 5–10 μg intracerebroventricularly. The trade-off is peripheral TREK-1 blockade in tissues like smooth muscle and cardiac myocytes, where the channel also regulates excitability. Monitor for cardiovascular effects if scaling dose upward, though no adverse events were reported in published studies at 2 mg/kg.

Stop melatonin immediately and inform your obstetrician at your next visit. Melatonin crosses the placental barrier and reaches fetal circulation at concentrations similar to maternal plasma, but single or short-term exposure (under two weeks) in the first trimester has not been conclusively linked to major congenital malformations in human observational studies. The concern is chronic exposure, which in animal models alters fetal circadian programming and delays sexual maturation in offspring. Your OB may recommend a detailed anatomy ultrasound at 18–20 weeks if exposure occurred during organogenesis (weeks 3–8), but isolated melatonin use for fewer than 10 days is unlikely to cause structural defects. Avoid all further use throughout pregnancy.

Test intermittent high-dose pulses versus daily low-dose continuous administration to identify optimal dosing schedules that maximize neuroplastic signaling while minimizing potential receptor desensitization. TrkA receptor pathways can undergo downregulation with sustained agonist exposure. A phenomenon observed with BDNF infusion studies. Pulsed dosing (e.g., 3 days on, 4 days off) might preserve receptor sensitivity while allowing sufficient NGF signaling to drive structural changes. Measure TrkA receptor density via radioligand binding or Western blot at multiple timepoints to correlate receptor expression with behavioral and neuroplastic outcomes across dosing schedules.

Discard the entire vial. Do not attempt to filter or use the solution. Pe-22-28 reconstituted properly with bacteriostatic water should be crystal clear with no visible particulate. Cloudiness indicates either peptide aggregation (from improper reconstitution technique, such as vigorous shaking instead of gentle swirling) or contamination. Aggregated peptides exhibit altered pharmacokinetics and may trigger immune responses in research subjects that confound study outcomes. Visible particles suggest stopper coring, glass fragmentation (if using glass vials), or microbial contamination. All of which compromise research validity and subject safety.

Yes, patients on hemodialysis or peritoneal dialysis should be excluded from SS-31 protocols. Although SS-31's molecular weight (640 Da) suggests dialyzability through standard high-flux membranes, interrupted clearance between sessions creates unpredictable plasma concentration spikes. Dialysis patients also exhibit uremic toxin accumulation and chronic inflammation that alters mitochondrial function in ways not yet characterized in SS-31 trials. No published pharmacokinetic data exists for SS-31 in end-stage renal disease (ESRD) populations. Until prospective trials establish dosing regimens and safety in dialysis-dependent patients, this represents an absolute contraindication. Researchers seeking to include ESRD patients should collaborate with nephrology teams and consider post-dialysis dosing with real-time plasma concentration monitoring.

Switch to a sustained-release formulation or split your dose. Take 0.5mg immediate-release at bedtime and another 0.5mg if you wake after 3–4 hours. Immediate-release melatonin clears plasma within 3–4 hours, which is why it's ineffective for sleep maintenance in people who wake at 2:00–4:00 AM. Sustained-release formulations maintain elevated concentrations for 6–8 hours, reducing the likelihood of middle-of-the-night awakenings. A 2021 study in Sleep Medicine found that adults over 55 using sustained-release melatonin reported 40% fewer nighttime awakenings compared to immediate-release at equivalent doses.

Yes, significantly. Mitochondrial function declines with age: cristae density decreases, cardiolipin content drops by 20–30%, and baseline ROS production increases due to reduced Complex I efficiency. The Circulation: Heart Failure study enrolled subjects with a mean age of 63 and baseline mitochondrial impairment, and SS-31 produced measurable improvements in ATP production rate and skeletal muscle fatigue resistance. If your declining performance is rooted in mitochondrial dysfunction rather than musculoskeletal limitation, SS-31 addresses the actual constraint. Pair this with resistance training to maintain muscle mass and you address both the power plant (mitochondria) and the machinery (contractile proteins).

PE-22-28 history would be shorter. The peptide's complex mechanism, requirement for subcutaneous or intranasal administration, and lack of oral bioavailability made it a poor commercial candidate by 1990s pharmaceutical standards. Small molecules with BBB penetration and oral dosing dominated CNS drug development. If early PE-22-28 researchers had pursued FDA approval instead of publishing academic findings, the compound would have faced prohibitively expensive Phase II trials without a clear patient population (the concept of "neuroinflammation" as a disease target didn't exist yet). Academic labs kept PE-22-28 alive by iterating on mechanism and generating data that later justified renewed interest. Commercial pressure often kills scientifically interesting compounds that don't fit immediate market needs. PE-22-28 benefited from being a research tool first.

You've likely exceeded the dose-response ceiling and entered the range where melatonin causes rebound effects. A dose-response study published in Sleep found that melatonin efficacy plateaus at 1–3mg. Doses above 5mg do not produce additional phase advancement and often result in next-day sedation, headache, and mood disruption. High doses also saturate receptors, meaning subsequent doses at normal levels produce blunted effects. The correct intervention is to taper down to 0.5–1mg taken at the biologically optimal time (3–5 hours before habitual sleep onset) and combine with light therapy in the morning to reinforce the circadian signal.

No pharmacokinetic interaction has been documented because the compounds act on different receptor systems and metabolic pathways. Melatonin undergoes hepatic CYP1A2 metabolism; Epithalon is degraded by peptidases and does not bind melatonin receptors. Concurrent use in research protocols is feasible. Melatonin administered nightly for circadian support while Epithalon is cycled monthly or quarterly. Monitor for additive sedation if melatonin doses exceed 3mg, though this is uncommon. The greater concern is that combining two compounds with distinct mechanisms makes it difficult to attribute observed effects to either one individually, complicating outcome interpretation.

Confirm TREK-1 channel expression and pharmacology in the target species before assuming Pe-22-28 efficacy translates directly. TREK-1 orthologs exist across mammals, but amino acid sequence divergence in the C-terminal domain. Where Pe-22-28 binds. Can alter IC50 and selectivity. Human TREK-1 shares 85–90% sequence identity with rodent channels, but subtle differences in lipid sensitivity and mechanosensitivity have been documented. Test Pe-22-28 in heterologous expression systems (HEK293 cells transfected with human TREK-1 cDNA) to establish concentration-response curves before committing to costly primate studies. For human iPSC-derived neurons, expect similar TREK-1 expression patterns to native hippocampal tissue, but validate with qPCR and Western blot before drawing mechanistic conclusions.

Evaluate whether the fourth peptide targets a mechanistically distinct pathway from the existing three. If it overlaps significantly with an existing compound, skip it. For example, adding Epithalon (a telomerase activator) to an ARA-290 + BPC-157 + TB-500 stack introduces a novel anti-aging mechanism without competing for growth factor receptors, making it a reasonable addition at 5-10 mg twice weekly. Conversely, adding both Semax and Dihexa to the same stack is redundant. Both target BDNF and HGF pathways for neurogenesis, and stacking them simultaneously produces diminishing returns while increasing peptide costs and injection burden. Limit stacks to three compounds beyond ARA-290 unless each peptide addresses a distinct biological endpoint (e.g., inflammation, tissue repair, immune modulation, metabolic function).

Conjugate PE-22-28 with a cell-penetrating peptide (CPP) like TAT (YGRKKRRQRRR) or penetratin to enable blood-brain barrier crossing. Unconjugated peptides show <0.1% CNS bioavailability after IP or subcutaneous injection. Custom synthesis labs can provide CPP-PE-22-28 fusions, though expect 3–4 week lead times and $1,200–$2,000 per batch. Alternative approaches include intranasal administration, which delivers peptides to the olfactory bulb and hippocampus via the trigeminal nerve pathway, bypassing the BBB entirely. Published intranasal protocols use 50–100 nmol total dose in mice with behavioral effects appearing within 6 hours.

Melatonin can advance circadian phase when administered 4–6 hours before habitual sleep onset, combined with morning bright light exposure upon waking. Start with 0.5 mg melatonin at 6:00 PM if your natural sleep onset is 2:00 AM, gradually advancing administration time by 15 minutes every 3 days as your sleep onset shifts earlier. This works because you're exploiting the phase response curve. Melatonin taken during the late biological afternoon/early evening advances the clock, while morning light reinforces this shift. Clinical trials in delayed sleep phase disorder patients achieved 60–90 minute phase advances within 2–3 weeks using this protocol, but compliance with consistent timing is essential. Irregular application produces no sustained benefit.

Purge the bubbles completely before administration, even if it means wasting 8–12 microliters of peptide solution. Air bubbles displace solution volume. A 10-microliter bubble in a 150-microliter dose represents 6.7% dose reduction. Tap the syringe barrel gently with the needle pointed upward until all bubbles rise to the top, then depress the plunger slowly until solution (not air) appears at the needle tip. If bubbles persist after three purge attempts, the reconstituted solution may be too viscous (indicating improper reconstitution) or the needle gauge too fine. Switch to a fresh 29-gauge syringe and redraw.

Melatonin is not an anxiolytic and has no direct GABAergic or serotonergic activity. If your sleep problem is driven by rumination, hyperarousal, or anxiety disorders, melatonin sleep medicine will not address the root cause. A 2019 meta-analysis of melatonin in generalized anxiety disorder and panic disorder found no significant reduction in anxiety symptoms or sleep latency compared to placebo. Anxious insomnia requires interventions that reduce sympathetic nervous system activation. Cognitive behavioral therapy for insomnia (CBT-I), magnesium glycinate, or GABAergic compounds like taurine or L-theanine. Not circadian modulators.